Business
-
AIR001 developer Mast Therapeutics will merge with AeroVanc and Molgradex developer Savara, the companies have announced. Savara’s current management team will lead the combined company, which will be called Savara Inc and which will trade… Read more . . .
-
Satsuma Pharmaceuticals, a spin out from Shin Nippon Biomedical Laboratories (SNBL) has closed a $12 million Series A financing co-led by RA Capital Management and TPG Biotech, the company said. Proceeds will be used to… Read more . . .
-
Days after its subsidiary Nicovations cancelled supply agreements with Bespak, British American Tobacco says that it and Kind Consumer “have reached a mutually satisfactory agreement on the financial aspects” on “a new approach to commercialize… Read more . . .
-
Bespak parent company Consort Medical has confirmed that British American Tobacco subsidiary Nicovations has terminated its supply agreements with Bespak for the Voke nicotine inhaler, effective immediately. According to Consort, Nicovations invoked a clause in… Read more . . .
-
Vectura and Mundipharma have signed an agreement for the development and commercialization of the VR2076 ICS/LABA/LAMA MDI, Vectura has announced. Skyepharma, which was acquired by Vectura earlier this year, had previously announced a development and… Read more . . .
-
Horizon Pharma has announced that Quinsair levofloxacin inhalation solution is now available in Canada for the treatment of P. aeruginosa lung infections in adult cystic fibrosis patients. Horizon acquired Quinsair when it acquired Raptor Pharmaceutical… Read more . . .
-
Sunovion has acquired exclusive US marketing rights to three Novartis DPIs for the treatment of COPD, the company has announced. The company said that it plans to market the Utibron (indacaterol/glycopyrrolate) Neohaler, Seebri (glycopyrrolate) Neohaler,… Read more . . .
-
Lonza Group will acquire capsule manufacturer and CDMO Capsugel from KKR for $5.5 billion, the company has announced. The deal has been approved by the boards of both companies and is expected to close by… Read more . . .
-
Cephalgia, a startup spun out of the University of Chicago, will receive $250,000 from the university’s Innovation Fund for development of intranasal IGF-1 for the treatment of migraine, according to the fund. The company was… Read more . . .
-
Intranasal drug developer Impel NeuroPharma has received $21 million in the initial tranche of a Series C financing round, with another $15 million available on completion of development and business milestones, the company said. Investors… Read more . . .
Featured event:

Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland


